Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of Utah, Salt Lake City.
Department of Otolaryngology-Head and Neck Surgery, University of California, Los Angeles.
JAMA Otolaryngol Head Neck Surg. 2022 Jun 1;148(6):507-514. doi: 10.1001/jamaoto.2022.0268.
The distance traveled by patients for medical care is associated with patient outcomes (ie, distance bias) and is a limitation in outcomes research. However, to date, distance bias has not been examined in rhinologic studies.
To evaluate the association of distance traveled by a cohort of patients with chronic rhinosinusitis with baseline disease severity and treatment outcomes.
DESIGN, SETTING, AND PARTICIPANTS: A total of 505 patients with chronic rhinosinusitis were prospectively enrolled in a multi-institutional, cross-sectional study in academic tertiary care centers between April 2011 and January 2020. Participants self-selected continued appropriate medical therapy or endoscopic sinus surgery. The 22-item Sinonasal Outcome Test (SNOT-22) and Medical Outcomes Study Short Form 6-D (SF-6D) health utility value scores were recorded at enrollment and follow-up. Data on the distances traveled by patients to the medical centers, based on residence zip codes, and medical comorbid conditions were collected.
Distance traveled by patient to obtain rhinologic care.
SNOT-22 and SF-6D scores. Scores for SNOT-22 range from 0 to 110; and for SF-6D, from 0.0 to 1.0. Higher SNOT-22 total scores indicate worse overall symptom severity. Higher SF-6D scores indicate better overall health utility; 1.0 represents perfect health and 0.0 represents death.
The median age for the 505 participants was 56.0 years (IQR, 41.0-64.0 years), 261 were men (51.7%), 457 were White (90.5%), and 13 were Hispanic or Latino (2.6%). These categories were collected according to criteria described and required by the National Institutes of Health and therefore do not equal the entire cohort. Patients traveled a median distance of 31.6 miles (50.6 km) (IQR, 12.2-114.5 miles [19.5-183.2 km]). Baseline (r = 0.00; 95% CI, 0.00-0.18) and posttreatment (r = 0.01; 95% CI, -0.07 to 0.10) SNOT-22 scores, as well as baseline (r = -0.12; 95% CI, -0.21 to -0.04) and posttreatment (r = 0.07; 95% CI, -0.02 to 0.16) SF-6D scores, were not associated with distance. There was no clinically meaningful correlation between distance traveled and mean comorbidity burden. Nevertheless, patients with a history of endoscopic sinus surgery were more likely to travel longer distances to obtain care (Cliff delta = 0.28; 95% CI, 0.19-0.38).
Although this cross-sectional study found that some patients appear more willing to travel longer distances for chronic rhinosinusitis care, results suggest that distance traveled to academic tertiary care centers was not associated with disease severity, outcomes, or comorbidity burden. These findings argue for greater generalizability of study results across various cohorts independent of distance traveled to obtain rhinologic care.
ClinicalTrials.gov Identifier: NCT02720653.
患者就医的距离与患者的预后相关(即距离偏倚),是预后研究的一个局限性。然而,迄今为止,在鼻科学研究中尚未检查过距离偏倚。
评估慢性鼻-鼻窦炎患者队列的就诊距离与基线疾病严重程度和治疗结局的关系。
设计、地点和参与者:2011 年 4 月至 2020 年 1 月期间,在学术性三级护理中心的多机构、横断面研究中,前瞻性纳入了 505 例慢性鼻-鼻窦炎患者。参与者自行选择继续接受适当的药物治疗或内镜鼻窦手术。在入组和随访时记录了 22 项鼻-鼻窦炎结局测试(SNOT-22)和医疗结局研究短表单 6 维度(SF-6D)健康效用值评分。根据居住邮政编码和医疗合并症,收集了患者到达医疗中心的就诊距离数据。
患者获得鼻科护理的就诊距离。
SNOT-22 和 SF-6D 评分。SNOT-22 的评分范围为 0 至 110 分;SF-6D 的评分范围为 0.0 至 1.0。SNOT-22 总分越高,表明整体症状严重程度越差。SF-6D 评分越高,表明整体健康效用越好;1.0 代表完全健康,0.0 代表死亡。
505 名参与者的中位年龄为 56.0 岁(IQR,41.0-64.0 岁),261 名男性(51.7%),457 名白人(90.5%),13 名西班牙裔或拉丁裔(2.6%)。这些类别是根据美国国立卫生研究院(National Institutes of Health)规定和要求描述和收集的,因此并不等同于整个队列。患者的平均就诊距离为 31.6 英里(50.6 公里)(IQR,12.2-114.5 英里[19.5-183.2 公里])。基线(r=0.00;95%CI,0.00-0.18)和治疗后(r=0.01;95%CI,-0.07 至 0.10)SNOT-22 评分,以及基线(r=-0.12;95%CI,-0.21 至 -0.04)和治疗后(r=0.07;95%CI,-0.02 至 0.16)SF-6D 评分与就诊距离均无相关性。就诊距离与平均合并症负担之间没有明显的临床相关关系。然而,有内镜鼻窦手术史的患者更可能长途跋涉寻求治疗(Cliff delta=0.28;95%CI,0.19-0.38)。
尽管这项横断面研究发现,一些患者似乎更愿意长途跋涉接受慢性鼻-鼻窦炎治疗,但结果表明,前往学术性三级护理中心的就诊距离与疾病严重程度、治疗结果或合并症负担无关。这些发现表明,研究结果在不同的患者群体中具有更大的普遍性,而与获得鼻科护理的就诊距离无关。
ClinicalTrials.gov 标识符:NCT02720653。